Cancer Family
Head and Neck Neoplasm
CI-CAN-00000021Explore in graph →
Non-malignant1,572 active trials17 approved drugs142 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000021Explore in graph →
Clinical trials
6,373 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03601507 | Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer | terminated | Phase 2 | 9 | University of ArizonaOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | terminated | Phase 1 | 13 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT04659369 |
| Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC |
| terminated |
| Phase 1 |
| 21 |
| Taizhou Mabtech Pharmaceutical Co.,LtdINDUSTRY |
| 1 |
| Apr 9, 2024 |
| clinicaltrials |
| NCT04936841 | Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma | terminated | Phase 2 | 5 | University of Wisconsin, MadisonOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT03602066 | Study Evaluating The Role of ClO2 on Mucositis for Pt. Undergoing Head/Neck Radiotherapy | terminated | Phase 2 | 14 | University of ArizonaOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06189482 | Intermittent Oral-esophageal Tube Feeding in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma(NPC) | terminated | N/A | 56 | Zeng ChanghaoOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05121948 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | terminated | Phase 1 | 35 | HiberCell, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06248840 | Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma | terminated | N/A | 56 | Zeng ChanghaoOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT03403361 | Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Outcomes of Patients Treated With Proton or Photon Therapy | terminated | N/A | 36 | Washington University School of MedicineOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT05099549 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | terminated | Phase 1 / Phase 2 | 11 | NKGen Biotech, Inc.INDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT04624113 | Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | terminated | Phase 1 | 13 | Washington University School of MedicineOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT01345136 | Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma | terminated | Phase 2 | 4 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04327999 | Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System | terminated | Phase 2 | 9 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 99 | CytomX TherapeuticsINDUSTRY | 4 | Jan 5, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04634825 | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer | terminated | Phase 2 | 62 | MacroGenicsINDUSTRY | 7 | Dec 20, 2023 | clinicaltrials |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Fusion Pharmaceuticals Inc.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | terminated | Phase 1 | 14 | IpsenINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT02285543 | A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients | terminated | Phase 2 | 10 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT02892487 | Evaluation of an Active Swallowing Rehabilitation on Quality of Life of Patients Treated by Radiotherapy for Head and Neck Cancer(RORC) | terminated | N/A | 183 | Rennes University HospitalOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT03618134 | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner | terminated | Phase 1 / Phase 2 | 19 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | terminated | — | 20 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04193293 | A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer | terminated | Phase 1 / Phase 2 | 2 | SecuraBioINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | terminated | Phase 1 | 5 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT02524275 | Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | terminated | Phase 2 | 14 | University of NebraskaOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT05116878 | Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma(EFFORTS) | terminated | N/A | 15 | Mayo ClinicOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT03714906 | Stellate Ganglion Block in Head and Neck Cancer Surgery | terminated | N/A | 22 | Augusta UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT03682055 | Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) | terminated | Phase 1 / Phase 2 | 14 | Cullinan Therapeutics Inc.INDUSTRY | 5 | Aug 15, 2023 | clinicaltrials |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors(ALpha-T) | terminated | Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT00707655 | Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy | terminated | Phase 1 / Phase 2 | 8 | GenmabINDUSTRY | 3 | Aug 3, 2023 | clinicaltrials |
| NCT02748564 | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | terminated | Phase 2 | 10 | Rutgers, The State University of New JerseyOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
| NCT03740100 | Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations(HNSCC) | terminated | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT03986593 | Cryoablation of Bone Metastases From Endocrine Tumors | terminated | N/A | 17 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT01824823 | Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence | terminated | Phase 2 | 3 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 28, 2023 | clinicaltrials |
| NCT02488629 | Study of SCB01A in Patient With Head and Neck Cancer | terminated | Phase 2 | 5 | SynCore Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 27, 2023 | clinicaltrials |
| NCT04618432 | Collection of Clinical Data and Specimens for Research on Head and Neck and Communication Disorders | terminated | — | 26 | National Institute on Deafness and Other Communication Disorders (NIDCD)NIH | 1 | Jun 13, 2023 | clinicaltrials |
| NCT03522584 | Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 6 | University of WashingtonOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT03020823 | To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer | terminated | Phase 2 | 10 | SynCore Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 5, 2023 | clinicaltrials |
| NCT03515603 | Endocrine Outcome of Surgery for Pituitary Adenoma | terminated | N/A | 36 | University of UlmOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT02345330 | Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC) | terminated | Phase 2 | 4 | OncoSec Medical IncorporatedINDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT03555721 | CytID Analysis of Oral Lesions | terminated | — | 18 | The University of Texas Health Science Center, HoustonOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT03823131 | Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat | terminated | Phase 2 | 14 | Chase Heaton, MDOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT02698111 | Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma | terminated | Phase 1 / Phase 2 | 20 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | May 8, 2023 | clinicaltrials |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | terminated | Phase 1 | 159 | Seagen Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT03642990 | NR in Chemo-induced Peripheral Neuropathy | terminated | Phase 2 | 5 | Donna Hammond, PhDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT03544099 | Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA | terminated | Phase 2 | 2 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 11, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 17, 2024source: clinicaltrials